{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:05:02Z","timestamp":1784559902090,"version":"3.55.0"},"reference-count":19,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"DOI":"10.61622\/rbgo\/2026rbgo32","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:43:23Z","timestamp":1784558603000},"source":"Crossref","is-referenced-by-count":0,"title":["Oteseconazole versus fluconazole in the treatment of acute candidiasis: a systematic review and meta-analysis"],"prefix":"10.61622","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-5118","authenticated-orcid":false,"given":"Elizabeth Honorato de","family":"Farias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7023-6254","authenticated-orcid":false,"given":"Ana Gabriela Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4789-6019","authenticated-orcid":false,"given":"Anderson Matheus Pereira da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3632-4806","authenticated-orcid":false,"given":"Lucas Silva","family":"Cabe\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0849-5435","authenticated-orcid":false,"given":"Laila Leite Pacheco","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1840-2953","authenticated-orcid":false,"given":"Pedro Lucas Machado","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5445-4528","authenticated-orcid":false,"suffix":"J\u00fanior","given":"Josvaldo da Silva","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-7269","authenticated-orcid":false,"suffix":"Junior","given":"Jos\u00e9","family":"Eleut\u00e9rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"47794","reference":[{"issue":"Suppl 2","key":"key20260720144318_B1","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","article-title":"Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of sexually transmitted infections treatment guidelines","volume":"74","author":"Nyirjesy","year":"2022","unstructured":"1 Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD. Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of sexually transmitted infections treatment guidelines. Clin Infect Dis. 2022;74 Suppl 2:S162-8. doi: 10.1093\/cid\/ciab1057","journal-title":"Clin Infect Dis"},{"issue":"1","key":"key20260720144318_B2","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00778-23","article-title":"Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial","volume":"68","author":"Wang","year":"2024","unstructured":"2 Wang X, Chen L, Ruan H, Xiong Z, Wang W, Qiu J, et al. Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial. Antimicrob Agents Chemother. 2024;68(1):e0077823. doi: 10.1128\/aac.00778-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"key20260720144318_B3","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3390\/jcm12165376","article-title":"Treatment of vulvovaginal candidiasis\u2014an overview of guidelines and the latest treatment methods","volume":"12","author":"Satora","year":"2023","unstructured":"3 Satora M, Grunwald A, Zaremba B, Frankowska K, \u017bak K, Tarkowski R, et al. Treatment of vulvovaginal candidiasis\u2014an overview of guidelines and the latest treatment methods. J Clin Med. 2023;12(16):5376. doi: 10.3390\/jcm12165376","journal-title":"J Clin Med"},{"issue":"5","key":"key20260720144318_B4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s12602-022-09997-3","article-title":"Comparing the effect of probiotic and fluconazole on treatment and recurrence of vulvovaginal candidiasis: a triple-blinded randomized controlled trial","volume":"15","author":"Mollazadeh-Narestan","year":"2023","unstructured":"4 Mollazadeh-Narestan Z, Yavarikia P, Homayouni-Rad A, Samadi Kafil H, Mohammad-Alizadeh-Charandabi S, Gholizadeh P, et al. Comparing the effect of probiotic and fluconazole on treatment and recurrence of vulvovaginal candidiasis: a triple-blinded randomized controlled trial. Probiotics Antimicrob Proteins. 2023;15(5):1436-46. doi: 10.1007\/s12602-022-09997-3","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"Spe1","key":"key20260720144318_B5","article-title":"Brazilian Protocol for Sexually Transmitted Infections 2020: infections causing vaginal discharge","volume":"30","author":"Carvalho","year":"2021","unstructured":"5 Carvalho NS, Eleut\u00e9rio J\u00fanior J, Travassos AG, Santana LB, Miranda AE. Brazilian Protocol for Sexually Transmitted Infections 2020: infections causing vaginal discharge. Epidemiol Serv Sa\u00fade. 2021;30(Spe1):e2020593. doi: 10.1590\/S1679-4974202100007.esp1","journal-title":"Epidemiol Serv Sa\u00fade"},{"issue":"11","key":"key20260720144318_B6","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","unstructured":"6 Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-47. doi: 10.1016\/S1473-3099(18)30103-8","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"key20260720144318_B7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/AOG.0000000000005673","article-title":"Assessment and treatment of vaginitis","volume":"144","author":"Mitchell","year":"2024","unstructured":"7 Mitchell CM. Assessment and treatment of vaginitis. Obstet Gynecol. 2024;144(6):765-81. doi: 10.1097\/AOG.0000000000005673","journal-title":"Obstet Gynecol"},{"issue":"6","key":"key20260720144318_B8","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","unstructured":"8 Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, et al. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. Am J Obstet Gynecol. 2022;227(6):880.e1-11. doi: 10.1016\/j.ajog.2022.07.023","journal-title":"Am J Obstet Gynecol"},{"issue":"18","key":"key20260720144318_B9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis","volume":"16","author":"Sobel","year":"2021","unstructured":"9 Sobel JD, Nyirjesy P. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol. 2021;16(18):1453-61. doi: 10.2217\/fmb-2021-0173","journal-title":"Future Microbiol"},{"issue":"6","key":"key20260720144318_B10","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","unstructured":"10 Daneshnia F, Almeida J\u00fanior JN, Ilkit M, Lombardi L, Perry AM, Gao M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023;4(6):e470-80. doi: 10.1016\/S2666-5247(23)00067-8","journal-title":"Lancet Microbe"},{"key":"key20260720144318_B11","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","unstructured":"11 Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"key20260720144318_B12","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","unstructured":"12 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: John Wiley & Sons; 2019.","edition":"2nd ed"},{"issue":"7","key":"key20260720144318_B13","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis","volume":"73","author":"Brand","year":"2021","unstructured":"13 Brand SR, Sobel JD, Nyirjesy P, Ghannoum MA, Schotzinger RJ, Degenhardt TP. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73(7):e1518-24. doi: 10.1093\/cid\/ciaa1204","journal-title":"Clin Infect Dis"},{"issue":"1","key":"key20260720144318_B14","doi-asserted-by":"crossref","first-page":"14095","DOI":"10.1038\/s41598-019-50410-x","article-title":"Diversity of vaginal microbiome and metabolome during genital infections","volume":"9","author":"Ceccarani","year":"2019","unstructured":"14 Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, et al. Diversity of vaginal microbiome and metabolome during genital infections. Sci Rep. 2019;9(1):14095. doi: 10.1038\/s41598-019-50410-x","journal-title":"Sci Rep"},{"issue":"11","key":"key20260720144318_B15","article-title":"Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis","volume":"8","author":"Liu","year":"2013","unstructured":"15 Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM, et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One. 2013;8(11):e79812. doi: 10.1371\/journal.pone.0079812","journal-title":"PLoS One"},{"key":"key20260720144318_B16","doi-asserted-by":"crossref","first-page":"103599","DOI":"10.1016\/j.micpath.2019.103599","article-title":"Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: are they different from normal microbiota?","volume":"134","author":"Pramanick","year":"2019","unstructured":"16 Pramanick R, Mayadeo N, Warke H, Begum S, Aich P, Aranha C. Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: are they different from normal microbiota? Microb Pathog. 2019;134:103599. doi: 10.1016\/j.micpath.2019.103599","journal-title":"Microb Pathog"},{"issue":"9-10","key":"key20260720144318_B17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.resmic.2017.02.005","article-title":"Candida and its dual lifestyle as a commensal and a pathogen","volume":"168","author":"Cauchie","year":"2017","unstructured":"17 Cauchie M, Desmet S, Lagrou K. Candida and its dual lifestyle as a commensal and a pathogen. Res Microbiol. 2017;168(9-10):802-10. doi: 10.1016\/j.resmic.2017.02.005","journal-title":"Res Microbiol"},{"issue":"8","key":"key20260720144318_B18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","volume":"1","author":"Sobel","year":"2022","unstructured":"18 Sobel JD, Donders G, Degenhardt T, Person K, Curelop S, Ghannoum M, et al. Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis. NEJM Evid. 2022;1(8):EVIDoa2100055. doi: 10.1056\/EVIDoa2100055","journal-title":"NEJM Evid"},{"issue":"Suppl 1","key":"key20260720144318_B19","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/ofid\/ofab466.916","article-title":"Susceptibility testing of oteseconazole (VT-1161) against clinical isolates from phase 3 clinical studies in subjects with recurrent vulvovaginal candidiasis","volume":"8","author":"Ghannoum","year":"2021","unstructured":"19 Ghannoum M, Degenhardt T, Person K, Brand S. Susceptibility testing of oteseconazole (VT-1161) against clinical isolates from phase 3 clinical studies in subjects with recurrent vulvovaginal candidiasis. Open Forum Infect Dis. 2021;8 Suppl 1:S459. doi: 10.1093\/ofid\/ofab466.916","journal-title":"Open Forum Infect Dis"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:43:26Z","timestamp":1784558606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/oteseconazole-versus-fluconazole-in-the-treatment-of-acute-candidiasis-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"alternative-id":["10.61622\/rbgo\/2026rbgo32"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2026rbgo32","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e-rbgo32"}}